Oral Insulin: Breakthrough Innovation at Biocon

Sachan, N and Kaipa, P and Nandkumar, A and Dhanaraj, C (2011) Oral Insulin: Breakthrough Innovation at Biocon. [Teaching Resource]

Full text not available from this repository. (Request a copy)


This case deals with the innovation challenges of a medium sized firm (under $1 billion) in an emerging economy (India), particularly the challenges of product development and commercialization. The management has to decide how to proceed with a promising novel formula for oral insulin - a promising therapeutic area both in terms of financial returns as well as social impact. The company had spent several years of R&D in getting the drug through Phase I and Phase II trials, and was entering the most critical stage, Phase III. The case is set in 2009, a period that was punctuated with a lot of economic uncertainty. Students are asked to decide if Biocon should go ahead with Phase III, and if so, whether it should be done locally or globally and with a partner or alone. The case also deals with transitioning research and development strategies in emerging markets, wherein firms that have traditionally focused on 'imitation' (or generic drugs) are moving to high risk drug discovery.

Affiliation: Indian School of Business
ISB Creiators:
ISB Creators
Nandkumar, A
Item Type: Teaching Resource
Uncontrolled Keywords: Creativity, Emerging Markets, Entrepreneurship, Operations management, Research & Development, Strategy technology
Subjects: Entrepreneurship
Business Strategy
Depositing User: Ilayaraja M
Date Deposited: 04 Jul 2019 13:56
Last Modified: 04 Jul 2019 13:56
URI: http://eprints.exchange.isb.edu/id/eprint/1234
Publisher URL: https://hbr.org/product/oral-insulin-breakthrough-...
Publisher OA policy: https://hbr.org/product/oral-insulin-breakthrough-innovation-at-biocon/W11276-PDF-ENG
Related URLs:

    Actions (login required)

    View Item View Item
    Statistics for DESI ePrint 1234 Statistics for this ePrint Item